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Lovastatin-induced inhibition of renal epithelial tubular cell prolifer-
ation involves a p21s activated, AP-1-dependent pathway. Proliferation
of tubular epithelial cells underlies the development of cystic lesions and
the subsequent impairment of renal function after renal mass reduction.
The effect of HMG CoA reductase inhibitors (HRI) on cell proliferation
was investigated in rat renal proximal tubular epithelial cells in primary
culture. Treatment of renal tubular epithelial cells with three different
HRI reduced fetal calf serum (FCS)-induced [3H]-thymidine incorpora-
tion (1C5() values were 0.7 I.LM, 1.7 .LM, and 1.6 j.M for simvastatin,
lovastatin, and compactin, respectively), and lovastatin blocked BrdUrd
incorporation, as assessed by immunocytochemical studies. The prolifer-
ative effect of cpidermal growth factor (EGF) was similarly abolished by
lovastatin. The effect of lovastatin (1 M) was prevented by 100 /.LM
mevalonate, 5 LM farnesyl-pyrophosphate and S /.LM geranylgeranyl-
pyrophosphate (in percent of control value, 31% vs. 102%, 60%, and 82%,
respectively) while cholesterol and other products of the mevalonate
pathway were inactive. Jmmunoblot analysis showed that lovastatin de-
creased membrane-bound p2l and inhibited FCS-induced c-fos and
c-jun protein expression. Furthermore, electrophoretic mobility shift assay
demonstrated the functional impairement of AP-1 DNA binding activity
in lovastatin-treated cells. In conclusion, these results demonstrate that
HRI are antiproliferative in epithelial tubule cells and that this effect is
exerted, at least in part, via inhibition of the p21"-activated and AP-1
dependent mitogenic cascade.
Renal tubule cells are mostly in a quiescent state in adult
kidney, and their turnover is accordingly low. However, tubule cell
proliferation may be induced under various pathophysiological
conditions and plays a major role in renal regeneration and repair.
Proximal tubule cell proliferation is one of the first steps of renal
reparation following acute ischemic or toxic injuries [11. Further-
more, proximal tubule cell proliferation is part of the initial
tubulointerstitial lesions that determine the progression of renal
damage occurring in the course of chronic renal diseases in animal
experimental models and in humans [2—41. Sustained tubule cell
proliferation is the hallmark of renal cysts caused by genetic or
acquired disorders and contributes to cyst expansion, which leads
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to the progressive destruction of renal parenchyma and further
degradation of renal function [1. Noteworthy is the fact that renal
mass reduction, induced by subtotal nephrectomy in rats, is
characterized by hyperplasia and cystic dilatations of tubular
structures, resulting in terminal renal failure despite minor gb-
merular and interstitial lesions [6—81.
Systemic and autocrine growth factors, such as epidermal
growth factor (EGF), are key mediators in the setting of renal
repair and compensatory renal growth [9]. Increased urinary
excretion of EGF, increased expression of EGF-receptor and
abnormal EGF-receptor polarization, and enhanced proliferative
response of cultured-cystic tubule cells to EGF have been dem-
onstrated in human autosomic polycystic kidney disease, delineat-
ing the elective role of this growth factor in states of sustained
tubule cell proliferation [10, 11]. EGF- and other tyrosine kinase
receptor-dependent signaling pathways activate the MAP kinase
cascade through the p2l"" molecular switch, ultimately leading to
activation of immediate early genes [12]. Elevated expression of
the protooncogenes c-myc, c-jun and c-fos was actually observed
at the onset of the tubular proliferative response to ischemic acute
tubular necrosis or subtotal nephrectomy, and in the hereditary
polycystic mouse, cpk/cpk [8, 13, 141. Interestingly, p2l'- and
c-myc-transformed mice present with rapid onset polycystic renal
disease [15, 16]. The p2l'" function is dependent upon isopreny-
lation, which determines its membrane anchorage and allows
direct specific protein interactions [17]. Thus, direct inhibitors of
p2l farnesylation have proved effective in inhibiting p2i'"
dependent-cell growth in vitro and in vivo [18]. On the other hand,
farnesyl is the first isoprenoid product of the mevalonate pathway
towards cellular cholesterol synthesis [19]. The HMG CoA reduc-
tase inhibitor (HRI) lovastatin competitively antagonizes meval-
onate synthesis and was shown to inhibit p2i' isoprenylation and
p21'-dependent cell growth in several transformed and untrans-
formed cell lines [20, 21]. Morover, lovastatin similarly abolished
geranylgeranylation of small GTP binding proteins involved in cell
cycle progression, which further emphasizes the interest for these
drugs as antiprobiferative agents [22]. While the antiproliferative
effect of HRI has been reported in transformed or untransformed
cell lines, the effect of these compounds on proliferation of
tubular epithelial cells in primary culture has not been assessed.
This appears all the more crucial as signaling pathways as well as
mevalonate pathway activity may be affected by virus or oncogene
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cell transformation [23, 24]. More importantly, although lova-
statin was shown to be antiproliferative in different cell systems, its
effects on downstream components of the p21'°'-activated mito-
genic cascade were not unequivocally established.
The aim of this study was to evaluate the effects of HMG CoA
reductase inhibitors on the p21sAP1 mitogenic cascade in rat
proximal tubule cells in primary culture. We show that HRI are
antiproliferative, and that this effect is exerted, at least in part, via
inhibition of the p2Y''-activated and AP-1-dependent mitogenic
pathways.
METHODS
Materials
Insulin, transferrin, dexamethasone, epidermal growth factor
(EGF), cholera toxin, deferoxamine mesylate, triiodo-L-thyro-
nine, sodium selenite, type 1 collagen, type 1 collagenase, hyal-
uronidase, phenyl methyl sulfonide fluoride (PMSF), mevalonic
acid lactone, farnesyl-pyrophosphate, geranylgeranyl-pyrophos-
phate, low density lipoprotein (human LDL, cholesterol 1,86
mg/mg protein), ubiquinone 50 (coenzyme Q10), N6-[isopentenyl]
adenine, dolichol, aprotinin, leupeptin, mevastatin (compactin),
3-[4,5-dimethylthiazol-2-yl-2,5 diphenyl-tetrazolium bromide
(MTT), genistein, herbimycin A were purchased from Sigma
Chemical Co. (St. Louis, MO, USA). lodoacetamide, apigenin,
wortmannin and a-hydroxyfarnesyl-phosphonic acid (HFPA)
were from Calbiochem (La Jolla, CA, USA). Pefabloc, 5-bromo-
2'-deoxyuridine-5'-monophosphate (BrdUrd) and fluorescein-
conjugated monoclonal antibody to BrdUrd were from Boehr-
inger Mannheim (Germany). Percoll was from Pharmacia
(Uppsala, Sweden). Anti-v-H-ras monoclonal antibody Y13-259
was from Oncogene Science. Anti-EGF receptor monoclonal
antibody and anti-alpha-tubulin monoclonal antibody were from
Sigma. °2P-ATP, [3H-methyl]thymidine and [3H]leucine were
purchased from Amersham (Amersham, UK). Lovastatin and
simvastatin were kindly provided by Merck Sharp & Dohme-
Chibret. Culture media and reagents, and T4 kinase were from
Gibco-BRL (Eragny, France). Plasticware was from Costar (Cam-
bridge, MA, USA). Animals were from Iffa Credo (France).
Sodium-dodecyl sulfate, 30% acrylamide/Bis (37:1) solution, and
nitrocellulose membrane were from BioRad. PoIy(dI.dC).poly-
(dl.dC) was from Pharmacia. AP-1 consensus oligonucleotide
sequence was ordered from Eurobio. Phosphorothioate-modifled
18-mcr oligonucicotides corresponding to the antisense sequences
flanking the translation initiation region of the murine mRNAs
for c-fos and c-jun were ordered from Genset. Their sequence is
as follows: c-fos antisense 5' -GGCGTTGAAACCCGAGAA-3'
and c-jun antisense 5'-CG1TTCCATCYFFTGCAGT-3' [25]. All
other reagents were of analytical grade.
The molecules of lovastatin, simvastatin, and compactin were
converted to their active form as described by Kita, Brown and
Goldstein [261. To produce the mevalonate salt, 13 mg of meva-
ionic acid lactone were incubated in 0.1 N NaOH (2 hr, 50°C, pH
7.4); the 0.1 M stock solution was stored at —20°C.
Cell culture
Rat proximal tubule epithelial cells were isolated as described
by Vinay, Gougoux and Lemieux [27] and grown as described for
other species with some modifications [28, 291. Briefly, kidneys
were removed aseptically from anesthetized 120 to 140 g Sprague-
Dawley rats, decapsulated and sliced in 1 mm-thick sections which
were kept at 4°C in HBSS supplemented with 10 mrvi N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes) and 5
mM D-glucose, pH 7.4 (HBS-Hepes). Cortex was separated from
medulla and incubated in a trypsinizing flask under gentle stirring
during 30 minutes, at 37°C in a 5% C02-95% air atmosphere.
Homogeneous populations of nephron segments were separated
by Percoll centrifugation. The mixture of tubules was suspended
in 42% Percoll made isotonic with 10 x concentrated HBS-
Hepes, and was centrifuged (17,000 rpm; 30 mm; 4°C). The F4
layer, made of proximal tubules, was suspended in HBS-Hepes
and centrifuged. The final pellet was suspended in culture me-
dium and tubules were seeded in culture plates that had been
coated with collagen. Serum-free culture medium consisted in a
1:1 (vol/vol) mixture of Ham's F-12 and Dulbecco's modified
Eagle's medium containing 25 mi Hepes, 21.5 mivi HCO3, 1 mM
Na pyruvate, 10 ml/Iiter of a 100 X non-essential amino acid
mixture, 4 mrvi L-glutamine, 50 U/mI penicillin, 50 /.Lg/ml strepto-
mycin, 50 nM Na selenite, 5 .tg/mi insulin, 35 jgJml transferrin, 5
flM triiodothyronine, 33 g/ml deferoxamine, 0.1 mg/mi bovine
serum albumin, 10 ng/ml EGF, 2.5 ng/ml cholera toxin, and 50 ntvi
dexamethasone. Fetal calf serum (FCS) 1% was added until the
first change. Two days before the conclusion of the experiment,
subconfluent cells were synchronized to the quiescent state by 28
hours incubation in serum- and hormone-free culture-medium.
DNA synthesis and cell viability assays
DNA and protein synthesis. Unless otherwise specified, HMG
CoA reductase inhibitors (HRI) and other chemicals were added
for the last 44 hours. Quiescent RPT cells grown in 48-well culture
plates were incubated with various growth factors or 5% FCS, and
1 itCi/ml [methyl3H-thymidine or [3H1-leucine for 20 hours. Cells
were then washed three times with ice-cold phosphate buffered
saline (PBS), and subjected to ice-cold 5% (wt/vol) trichioroacetic
acid (TCA) for 45 minutes. After washing with PBS, the TCA-
precipitable material was dissolved in 0.2 N sodium hydroxyde and
the incorporation of radioactivity was measured by scintillation
counting.
Immunocytochemical study of BrdUrd incorporation. RPT cells
grown on coverslips were synchronized to quiescence and stimu-
lated with 5% FCS during 20 hours. BrdUrd (10 tM) was added
for the last six hours. At the end of the incubation period the cells
were rinsed twice with cold PBS, fixed on ice with cold methanol
for 10 minutes, and air-dried. After permeabilization with PBS-
Triton X-100 (0.1%, 3 mm) and incubation in PBS-FCS (1:1,
vol:vol; 15 mm), DNA was denatured by a one hour incubation in
2 N HC1, the cells were washed with borate buffer (0.1 N; pH 8.5)
and were incubated 60 minutes with anti-BrdUrd fluorescein-
conjugated antibody in PBS-Tween 0.5% (PBST) containing 0.1%
BSA, at room temperature in the dark. Coverslips were then
washed with PBST, mounted on glass and the cells were analyzed
under fluorescence microscope.
Cell viability. Cell viability was assayed by measuring the mito-
chondrial reduction of the tetrazolium salt MiT. Quiescent RPT
cells grown in 48-well culture plates were incubated with various
concentrations of HRI and stimulated with FCS (5%, 20 hr). MIT
(5 mg/mI in PBS; final concentration 0.5 mg/mI) was added to
each well for the last four hours; the cells were incubated at 37°C
in the dark. After incubation the medium was discarded, and the
formazan precipitate was soluhilized by addition of DMSO and
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gentle shaking for 10 minutes. Optical density was read at 540 nm
on a microplaque reader. The formation of formazan blue crystal
measured by this technique is a reliable index of the number of
living cells [301.
Immunoblotting
For the preparation of membrane fractions, cells were washed
twice with cold PBS, scraped on ice in 1.5 ml PBS, and then
pelleted. Cells were sonicated in 1 ml PBS containing 2 mi EDTA
and 1 mrvt Pefabloc. After removal of cell debris by centrifugation,
membranes were collected at 100,000 g for 30 minutes. The
membrane fraction was redissolved by sonication in lysis buffer A
(100 mri Tris pH 7.4, 300 mrvt NaC1, 2 mrvi EDTA, 1% Triton
X-100, 0.1% SDS, 5 mi iodoacetamide, 1 .tM leupeptin, 1 mM
Pefabloc). For the preparation of whole cell extracts, cells were
washed twice with cold PBS, incubated 30 minutes on ice in lysis
buffer B (50 mivi Tris pH 8.0, 150 mr't NaC1, 0.1% SDS, 100 jig/mI
PMSF, I jig/mI aprotinin, 1% Nonidet P 40, 0.5% sodium
deoxycholate) scraped and centrifuged (13,000 >< g, 5 mm, 4°C).
Protein concentrations in supernatants were determined by the
method of Bradford [31].
SDS-PAGE was performed on 12% gels (Western blotting of
p2l"' protein), 10% gels (Western blotting of tubulin and of c-fos
and c-jun proteins), or 7% gels (Western blotting of EGF-
receptor protein) as described [32]. The resolved proteins were
transferred onto a nitrocellulose membrane, and the gel was
stained with Ponceau red to verify equal loading and uniform
transfer of the proteins. The nonspecific sites on the membrane
were blocked by incubation at room temperature for one hour in
7.5% nonfat dairy milk powder in PBST. The membrane was
washed with PBST and incubated overnight at 4°C with the
primary antibody in PBST containing 10% FCS [33]. The mem-
brane was washed with PBST, incubated 30 minutes in PBST-
7.5% milk, and incubated one hour at room temperature with
horseradish peroxidase-conjugated secondary antibody (Amer-
sham) in PBST containing 10% FCS. The membrane was further
washed with PBST and incubated 30 minutes in PBST containing
400 mM NaCI, followed by detection with enhanced chemilumi-
nescence (ECL kit, Amersham).
Electrophoretic mobility shift assay
Preparation of nuclear extracts. Nuclear extracts were prepared
as described [34]. RPT cells were washed twice and scraped in
ice-cold PBS, resuspended and shaked in 400 pJ of cold buffer A
(10 mrvi HEPES, pH 7.9, 10 mrvi KC1, 1.5 m'vi MgCl2, 2 mM
dithiothreitol, 1 mt EDTA, 1 mrvi PMSF, 5 jiM leupeptin, 5 jiM
aprotinin), and allowed to swell for 10 minutes on ice. The nuclei
were collected by centrifugation (3,500 X g, 15 mm), and resus-
pended in 25 jil of hypertonic buffer (20 mvi HEPES, pH 7.9, 1 M
KC1, 25% glycerol, 1.5 mt MgC12, 0.2 mrvi EDTA, 2 mt dithio-
threitol, 1 m'vi PMSF, 5 jiM leupeptin, 5 p.M aprotinin). The
suspension was incubated 30 minutes on ice, centrifugated at
25,000 X g for 20 minutes at 4°C, and the supernatant was used as
the nuclear extract and kept frozen at —80°C after measurement
of the protein content.
Electrophoretic mobility shift assay. AP-1 consensus oligonucle-
otide (5 '-TAAAGCATGAGTCAGACACCTC-3') was radiola-
beled by incubating 4 1id of 25 jiM oligonucleotide with 5 p.1 of 5 X
forward kinase buffer (Gibco), 10 p.1 of '32P-ATP, and 25 U of T4
kinase (final volume 25 p.!) at 37°C for one hour before annealing
Table 1. Effects of FCS and growth factors on DNA synthesis
Condition
Thymidine incorporation
cpm/well/20 hr
Basal 2691 270
FCS 5% 5149 407h
EGF nglml
5 3394 338
10 4480 295
25 4626 562'
50 4532 207h
100 5053 528h
IGF-1 ng/ml
10 2536 804
100 2801 843
Insulin /.Lg/ml
5 2583 340
Subconfluent RPT cells were incubated with [3H}thymidine during 20
hours in serum- and hormone-free medium (basal) or with FCS, EGF,
IGF-1 at indicated concentrations or insulin (5 jig/mI). Data are mean
SEM of 4-7 experiments which were determined in triplicate.
ap <0.05
bp <0.01
at 95°C for 10 minutes. Nuclear extract (10 jig) was mixed with I
jig poly(dIdC)poly(dIdC) in a binding buffer (50 m'vi NaC1, 20 mM
HEPES pH 7.9, 5 mrvi MgC12, 2 mrvi DIT, 20% glycerol, 1 JiM
leupeptin, 1 jiM aprotinin). The labeled probe was added, and the
reaction mixture was incubated for 30 minutes at 4°C. Competi-
tion studies were performed by adding excess of unlabeled AP-1
consensus oligonucleotide, or of unrelated oligonucleotide
(NF-1: 5 '-G'TTVFGGCTTGAAGCCAATATGAG-3'). The sam-
ples were then separated by 6% polyaciylamide gel electrophore-
sis in 0.5 X TBE buffer. The gel was dried under vacuum and
subjected to autoradiography.
Presentation of data
Results are mean SE of at least three different experiments
(N) in which triplicates were obtained. One-way or two-ways
analyses of variance were performed and, when allowed by the F
value, results were compared by the modified I-test [35].
RESULTS
Proximal tubule cell proliferation is induced through the
growth factor-tyrosine kinase receptor/MAP kinase/AP-L
dependent pathway
The proximal origin of renal proximal tubular epithelial cells
was confirmed by positive alkaline phosphatase staining and
evidence of Na-dependent glucose uptake (data not shown). DNA
synthesis, as measured by [3H]-thymidine incorporation, was
stimulated in a concentration-dependent manner by EGF and
FCS. As previously reported [36], insulin and IGF-1 are less
potent mitogens for renal proximal tubule cells and their effect did
not reach statistical significance (Table 1).
FCS-stimulated renal proximal tubular epithelial cells were
incubated with several different inhibitors of the growth factor-
tyrosine kinase receptor/MAP kinase/AP-1 pathway. As shown
Table 2, tyrosine kinase inhibitors genistein and herbimycin A,
protein farnesyl transferase inhibitor HFPA, and MAP kinase
inhibitors apigenin and wortmannin induced significant inhibition
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Table 2. Effects of growth factor-receptor/MAP kinase/AP-1 inhibitors
on renal cell proliferation
Condition
Thymidine MTT
incorporation (OD)
% of control value
Genistein ig/ml 1
5
10
103 5.5 86 5.4
31 4.6" 82 2.6a
24 137b
Herbimycin A 2M 0.1
0.25
0.5
1
80 6.7a 85 6.6
60 71" 82 5.l
42 71b 71 iT
22 45b 67 5.6a
HFPA ji 0.5
1
5
10
25
85 7.4
82±2.9a
77±2.4a
71 4.1'
59±2
Wortmannin p.M 0.1
0.25
0.5
1
2.5
82 5.3 94 5.969 43 83 3.5
62 4.8a 76 2.3"
55 65" 80 3.2"
33 25h 70 59b
Apigenin p.si 1
10
25
50
106 4.7 95 21.9
88 12.9 84 3.0
69 21.4"
22 99h 67 9.5"
c-jun, c-fos antisense psi 0.5
1
5
10
94 6.1
93±7.5
83±5.2"
74 5.3"
Subconfluent RPT cells were incubated with various concentrations of
antagonists during 48 hours. [3H]thymidine incorporation study or MTF
test were performed as described. Data are mean SEM of 2-8 experi-
ments, which were determined in triplicate.
ap < 0.05, "p < 0.01.
of thymidine incorporation. Noteworthy, the effect of these an-
tagonists on cell viability, as assessed by MTT test, was much less
pronounced, thus reflecting an elective antiproliferative effect.
Downstream inhibition of AP-1 formation via c-fos and c-jun
antisense oligodeoxynucleotides significantly reduced FCS-stimu-
lated RPT cell proliferation. In contrast, control 18-mer oligonu-
cleotide of unrelated sequence exerted no significant effect (data
not shown). These results indicated that proximal tubule cell
proliferation was induced through the growth factor-tyrosine
kinase receptor/MAP kinase/AP-1 dependent pathway.
HMG CoA inhibitors (HRI) reduce proximal tubule cells
proliferation
Lovastatin inhibited DNA synthesis in renal proximal tubular
epithelial cells in a concentration-dependent manner, as reflected
by inhibition of [3H]-thymidine incorporation (Fig. IA); this effect
was reproduced with simvastatin and compactin, two other HMG
CoA reductase inhibitors, The effect of lovastatin on [3HJ-
thymidine incorporation in renal proximal tubular epithelial cells
was less pronounced after only 24 hours of incubation: no
significant inhibition was observed following 24 hours of incuba-
tion with I p.M lovastatin, while 5 p.M or 25 p.M lovastatin remained
active (98 3.8%, 60 8.4% and 47 11.5% of control value
with 1 JIM, 5 p.M or 25 p.M lovastatin, respectively). Renal proximal
tubular epithelial cells were incubated 48 hours with HRI in
subsequent experiments. Half-maximal inhibitory concentrations
were in the niicromolar range (0.7 JIM, 1.7 p.M and 1.6 p.M for
*flHhth
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Fig. 1. Effects of HMG CoA reductase inhibitors on F3Hlthymidine
incorporation in RPT cells. Subconfluent cells wcrc incubated 48 hours
with various concentrations of lovastatin and/or mevalonatc, and fetal calf
serum (FCS) (5%) and 3Hjthymidine were added during the last 20
hours. A) Incubation with lovastatin alone. Results arc mean SEM of 5
to 7 experiments performed in triplicate. "P < 0.05 versus control
(FCS-stimulated cells incubated without lovastatin). (B) Renal proximal
tubular epithelial cells were incubated with various concentrations of
lovastatin (U), simvastatin (•), or compactin (A). Results are mean of 3
to 6 experiments performed in triplicate, and expressed as percent of
control value measured in FCS-stimulated renal proximal tubular epithe-
hal cells incubated without inhibitors. For better legibility, error bars arc
not shown hut consistently represented less than 15% of values. (C) Renal
proximal tubular epithelial cells were incubated in absence (control, ) or
in presence of 5 () or 25 p.M () lovastatin, and with various concentra-
tions of mevalonate. Results are mean of 3 to 6 experiments performed in
triplicate and expressed as percent of control value measured in FCS-
stimulated renal proximal tubular epithelial cells incubated in absence of
lovastatin. *p < 0.05 versus FCS-stimulated cells incubated without
inhibitors.
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Fig. 2. linmunocytochemical analysis of
BrdUrd incorporation. Subconfluent renal
proximal tubular epithelial cells were incubated
with or without lovastatin (5 LM) and/or
mevalonate (500 /LM). Renal proximal tubular
epithelial cells were stimulated with FCS (5%)
and incubated with 10 j.tM BrdUrd during six
hours. (.4) control; (B) lovastatin; (C)
mevalonate alone; (D) lovastatin plus
mevalonate.
simvastatin, lovastatin and compactin, respectively; Fig. 1B). A
marked reduction of nuclear BrdUrd staining was observed on
immuno-cytochemical studies in lovastatin-treated RPT cells (5
/LM, 48 hr; Fig. 2). The elective stimulatory effect of 100 ng/ml
EGF on [3H]-thymidine incorporation (2319 289 cpm/well to
4219 74 cpm/well, P < 0.05) was similarly abolished in 5 M
lovastatin-treated RPT cells (1266 286 cpm/well to 1362 469
cpm/well, P = NS).
HMG CoA reductase inhibitors (HRI)-induced inhibition of
DNA synthesis was not the consequence of a nonspecific cytotox-
icity as shown by the prevention of reduced [3HJ-thymidine
incorporation and reduced nuclear BrdUrd staining obtained with
mevalonate, the immediate product of HMG CoA reductase
(Figs. IC and 2). Lovastatin (5 /.tM, 48 hr) reduced the number of
cells per well as compared to FCS-stimulated or quiescent,
untreated cells (29,000 cell/well, 39,000 cell/well, 16,000 cell/well,
in quiescent cells, FCS-stimulated, and FCS-stimulated lovastatin-
treated cells, respectively (Fig. 3). However, the HRI-concentra-
tion threshold for a decrease in the number of living cells, as
measured by MTT test, or for inhibition of cellular protein
synthesis, as measured by [3H1-leucine incorporation, were con-
siderably higher than the threshold for a decrease of 3H]-
thymidine incorporation (Fig. 4). Along the same line, the lowest
HRI concentrations that inhibited thymidine incorporation (up to
I M) did not decrease total protein content (23.7 1.2 pg/well,
21.0 1.3 j.tg/well, and 22.2 1.2 .tg/well in control, 1 jIM
lovastatin- and 1 jIM compactin-treated RPT cells, respectively,
P = NS). This suggested that the inhibition of DNA synthesis was
indeed an initial step in HRI-antiproliferative effect.
Reversibility of growth inhibition
Lovastatin inhibited DNA synthesis irs RPT cells stimulated
with cholesterol-containing FCS, thus suggesting that its effect was
not the consequence of decreased cholesterol availability. More-
over, medium supplementation with LDL-cholesterol (10 or 50 jtg
cholesterol/mi), the natural substrate of exogenous cholesterol
metabolic pathway, did not modify lovastatin-induced inhibition
Fig. 3. Light microscopy aspects of RPT cells in primary culture. Three
days after isolation, renal proximal tubular epithelial cells were changed to
serum- and hormone-free medium, and incubated 48 hours with vehicle,
or lovastatin alone (5 jays) or together with mevalonate (500 jIM), FPP (10
or GGPP (10 jIM). (B, C, D, E, F) RPT cells were incubated with 5%
FCS during the last 20 hours. Microphotographs were taken under phase
contrast microscope. (A) Renal proximal tubular epithelial cells at day 3.
(B) Control-renal proximal tubular epithelial cells at day 5. (C) Lovasta-
tin-treated renal proximal tubular epithelial cells at day 5. (D) Lovastatin-
and nievalonate-treated renal proximal tubular epithelial cells at day 5.
(F) Lovastatin- and FPP-treated renal proximal tubular epithelial cells at
day 5. (F) Lovastatin- and GGPP-treated renal proximal tubular cpithelial
cells at day 5.
c 
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Fig. 4. Cell viability assays. RPT cells were incubated 48 hours with
various concentrations of HMG CoA reductase inhibitors and stimulated
with 5% fetal calf serum (FCS) during the last 20 hours. (A) 3-[4,
5-dimcthylthiazol-2-yl]-2,5 diphenyl-tetrazolium bromide (MTT) was
added for the last four hours, and optical density read at 540 nm after
solubilization in DM50. (B) Protein synthesis (20-hours of [3H]leucinc
incorporation) was measured. Results are the means of 3 to 7 experiments
performed in triplicate. For better legibility, error bars are not shown but
consistcntly represented less than 15% of values. Symbols are: (U)
lovastatin; (•) compactin; (A) simvastatin. *p < 0.05 versus FCS-
stimulated cells incubated without 11MG CoA reductase inhibitor.
of DNA synthesis (Table 3). Isopentenyl-adenine (5 or 50 gM),
ubiquinone 50 (10 jiM), and dolichol (10 or 25 j.tM), other
intermediates of cholesterol synthesis down the mevalonate path-
way, were also totally ineffective (Table 3).
Farnesyl-pyrophosphate (FPP), the common cytosolic precur-
sor of isoprenylation and of cholesterol synthesis, significantly
reduced the antiproliferative effect of up to 5 j.rM lovastatin (Fig.
5A). This protective effect was reproduced with geranylgeranyl-
pyrophosphate (GGPP), another isoprenoid compound. As com-
pared to mevalonate, the protective effects of FPP and GGPP
against lovastatin-induced inhibition of thymidine incorporation
Control Lovastatin
Thymidine incorporation
Condition % of control value
Basal 100 43 6.6
Dolichol pg/mI
10 108±5.7 56±13.6
25 90 9.0 37 21.7
Ubiquinone pg/ml
10 121 19.7 52 17.8
IPA jig/mI
5 118 18.8 33 9.7
50 110 21,8 55 19.0
100 90±11.0 35±3.4
LDL-Chol pg/mI
10 100 5.7 59 5.9
50 109±12.3 39±5.4
were apparent from much lower concentrations (Fig. 5 B, C).
* GGPP was much more effective than FPP at any concentration
used.
Mechanism of lovastatin antiproliferative effect
The inhibitor of farnesyl-protein transferase HFPA [37] con-
centration-dependently inhibited FCS-stimulated [3Hj-thymidine
incorporation in RPT cells (80 5.0% in 5 jiM HFPA-treated
RPT cells, P < 0.05; Fig. 6A). Sub-maximal concentrations of
lovastatin and HFPA had non-additive inhibitory effects on
FCS-stimulated [3Hj-thymidine incorporation, suggesting an at
least partially common mechanism of action (Fig. 6B).
Immunoblot analysis revealed that lovastatin decreased the
amount of membrane bound-p21' in FCS-stimulated RPT cells.
In contrast, EGF receptor protein expression was unaffected by
lovastatin treatment (Fig. 7A). Downstream steps along p21tm5
dependent mitogenic pathway were equally inhibited in lovasta-
tin-treated RPT cells. The time course of c-fos protein expression
following stimulation with serum exhibited a maximum after 90
minutes of incubation and a subsequent decrease with no appar-
ent activation after 18 hours (Fig. 8B). As shown Figure SC,
lovastatin abolished c-fos protein expression in serum-stimulated
RPT cells. A low level of c-jun protein expression was observed in
total cell extracts from unstimulated cells, and similarly increased
following serum-stimulation (Fig. SD). As shown by immunoblot-
ting, lovastatin also inhibited c-jun protein expression in FCS-
stimulated RPT cells. In contrast, expression of the microtubule-
associated protein tubulin was unaffected hy lovastatin treatment
(Fig. SA). Finally, lovastatin-induced decrease of membrane
bound p2l, and of c-fos and c-jun protein expression were all
prevented by 500 jiM mcvalonate (Figs. 7 and 8). These results
thus confirmed that lovastatin-induced decreases of c-fos and
c-jun and of membrane bound p21"5 were specific steps of its
antiproliferative effect.
A Table 3. Effects of products of the mevalonate pathway on lovastatin-induced inhibition of RPT cells proliferation
1.0
0.9
0.8
0.7
0.6
0.5
d 0.4
0.3
0.2
0.1
0.0
6000
5000
Ce0'- 4000
3000
oE
2000I
0D
1000
0
0.0 2.5 5.0
Inhibitor, pMB
*
7.5 10.0 Renal tubular epithelial cells were incubated 48 hours in the absence or
in presence of 5 JiM lovastatin, with or without 500 jiM mevalonate, 10 or
25 jig/mI dolichol, 10 jig/mI ubiquinone, 5 or 50 jig/mI IPA, and 10 or 50
jig/mI cholesterol (LDL-cholesterol). Fetal calf serum (FCS) and [3H]thy-
midine were added for the last 20 hours. [3Hithymidine incorporation in
FCS-stimulated cells (control) was 5,219 624 cpm/well. Results are
mean SUM of 4-6 experiments performed in triplicate, and expressed as
percent of control value measured in renal tubular epithelial cells incu-
bated with FCS alone.
*
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Fig. 6. Effect of hydroxyfarnesyl-phosphonic acid on [3H] thymidine in-
corporation. (A) Renal proximal tubular epithelial cells were incubated 48
hours with various concentrations of HFPA (), and with 5% fetal calf
serum (FCS) and [3Hlthymidine during the last 20 hours. Results are
mean suM of 6 experiments performed in triplicate, and expressed as
percent of control value measured in renal proximal tubular epithelial
cells incubated without HFPA. (B) RPT cells were incubated 48 hours in
absence (U) or in presence of 5 M HFPA (), and with or without 5 jsM
lovastatin. Cells were stimulated with 5% FCS during the last 20 hours.
Results are mean SEM of 4 experiments performed in triplicate, and
expressed as percent of control value measured in renal proximal tubular
cpithelial cells incubated with FCS alone. *p < 0.05 versus homologous
control, &p < 0.05 versus FCS-stimulated and untreated cells.
to 7), whereas unrelated oligonucleotide sequence had no effect
(lane 8). As shown in Figure 9B, lovastatin (10 .tM, 20 hr)
completely prevented FCS-induction of AP-1 binding activity in
RPT cells (lanes 3 to 4). Much like the effects of lovastatin on
Fig. 5. Effects of isoprenoids on lovastatin-induced inhibition of F3H1 thy-
midine incorporation. (A) Renal proximal tubular epithclial cells were
incubatcd 48 hours in the absence or in presence of 10 jM farnesyl-
pyrophosphate (FPP) or 10 tM geranylgeranyl-pyrophosph ate (GGPP)
and with various concentrations of lovastatin. Cells were stimulated with
5% FCS during the last 20 hours. Symbols are: (U) control; () FPP 10
p.N4; (Li) GGPP 10 JLM. (B and C) Renal proximal tubule epithelial cells
were incubated 48 hours in the absence (U) or in presence of 5 /LM
lovastatin (, LI) and with various concentrations of FPP (B) or GGPP(C), and stimulated 20 hours with 5% fetal calf serum (FCS). Results are
mean SCM of 5 experiments performed in triplicate, and expressed as
percent of control value measured in renal proximal tubular epithelial
cells incubated with FCS alone. *p < 0.05 versus control.
AP-1 binding activity was evidenced in nuclear extracts from
FCS-treated RPT cells (Fig. 9A, lane 2). Addition of excess
unlabeled AP-1 oligonucleotide consensus sequence concentra-
tion-dependently inhibited shift band formation (Fig. 9A, lanes 3
a----
r
-a--
EGF-R -
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upstream components of the p2lv activated AP-1 mitogenic
pathway, the decrease of AP-1 binding activity was totally pre-
vented by 500 /.tM mevalonate (lane 5).
DISCUSSION
In this study, we have demonstrated that: (a) lovastatin and two
other HRI inhibited RPT cells proliferation; (b) this effect was
related, at least in part, to inhibition of p2Y"' isoprenylation and
a resulting downstream block on the c-fos-, c-jun-dependent
mitogenic pathway.
Proximal tubule cells in primary culture are highly differenti-
ated and allow a comprehensive approach of the phenomena
occurring in vivo in renal regeneration and repair. Interruption of
the growth factor receptor/MAP kinase/AP-1 pathway at various
steps of the cascade produced an antiproliferative effect in rat
renal tubule cells (Table 2). These results demonstrated the main
role of this cascade in RPT cell proliferation. On the other hand,
autocrine production of growth factors is a well known feature of
renal tubule cells that may have accounted, along with previous
stimulation with long-lasting action growth factors, for the ele-
vated [3H]thymidine incorporation in serum- and hormone-de-
prived RPT cells [38]. Accordingly, substantial level of c-jun
protein expression and of AP-1 binding activity in unstimulated
cells (Figs. 8D and 9) is additional evidence for the fact that
unstimulated RPT cells are not completely quiescent, which may
have offset the growth-stimulatory effect of IGF-1 and insulin
(Table 1).
As judged from the MTT assay, HRI displayed no apparent
cytotoxicity at concentrations that exerted a marked inhibition of
FCS-stimulated [3H]-thymidine incorporation. Incubation of RPT
cells with lovastatin during 48 hours led to sustained inhibition of
DNA synthesis and of cell replication, and resulted in a final
decrease in cell number as compared to FCS-stimulated cells. The
reversibility of lovastatin inhibitory effect obtained with meval-
onate and isoprenoids is another clue of the specificity of its
antiproliferative mechanism.
The antiproliferative effects of lovastatin in RPT cells involved
a non-sterol mevalonate derived compound as demonstrated by
the protective effects of farnesyl- and geranylgeranyl-pyrophos-
phate. Moreover, the effects of lovastatin were at least partially
reproduced when protein farnesylation was inhibited with the
protein farnesyl transferase antagonist EIFPA. This suggested that
isoprenylated-proteins were involved in lovastatin-sensitive RPT
cells proliferation. Western blot analysis of membrane fractions of
RPT cells directly demonstrated a lovastatirt-induced decrease of
p21" protein and its reversibility with mevalonate. In addition to
p21', a wide array of cellular proteins are either farnesylated or
Fig. 7. Western blot analysis of membrane
bound p21". Renal proximal tubular epithelial
cells were incubated 28 hours in presence or in
absence of 5 jtM lovastatin and/or 500 sM
mevalonate and stimulated 45 minutes with
fetal calf serum (FCS). Membrane fractions
were prepared, and proteins were separated by
SDS-PAGE and immunoblotted.
geranylgeranylated, depending on their carboxyterminal amino
acid sequence [39]. Besides inhibition of p2l'" farnesylation,
lovastatin also prevented isoprenylation and function of cell-
growth related proteins, among which are other members of
p2i'-superfamily and gamma subunit of heterotrimeric G pro-
tein [22, 40]. The highly potent reversibility obtained with gera-
nylgeranyl-pyrophosh ate may have indicated the involvement of a
geranylgeranylated protein. Accordingly, in a mouse fibroblastic
cell line, inhibition of protein geranylgeranylation by lovastatin or
by a specific antagonist resulted in a GO/Gi cell cycle arrest,
whereas a specific farnesyltransferase inhibitor was ineffective
[221. Farnesylation is a critical modification for membrane asso-
ciation and activity of p2i protein; however, K-ras 4B protein
and Ha-ras protein may undergo geranylgeranylation and are
potential candidates [41, 42]. Indeed, several reports have estab-
lished that lovastatin inhibited membrane anchoring of different
suatypes of p2l'" [21, 43]. On the other hand, a crucial role of
geranylgeranylated RhoA in the transmission of the proliferative
signal downstream of ras was demonstrated in rat fibroblasts [44].
This mechanism might explain the striking effect of geranylgera-
nyl-pyrophosphate in our model, even though inhibition of p2l
isoprenylation was a primary effect of lovastatin. Accordingly, the
time course of lovastatin antiproliferative effect was coincident
with the half-life of p2V"' (20 to 24 hr) rather than with the
shorter half-life of RhoA (2 hr) [45]. Interestingly, the reversal of
p21-dependent cell growth obtained with various protein fame-
syl transferase inhibitors was specific of p21'-transformation
since neither untransformed or raf 1-, v-mos- and v-raf-trans-
formed cells were affected [42, 46]; the basis for this selectivity is
not fully understood [18]. Finally, the cellular uptake and metab-
olism of exogenously added farnesyl- and geranylgeranyl-pyro-
phosphate are not known, and may have been limiting factors
accounting for differences in their capacity for preventing the
lovastatin effect.
The mitogenie signaling pathway in renal tubule cells involves
tyrosine kinase-dependent activation of the MAP-kinase cascade
and formation of AP-1 transcription complex. Interestingly, lova-
statin reduced MAP kinase activation by insulin in rat fibroblasts
[471. C-los and c-jun are immediate early genes and are rapidly
transcriptionally induced following serum stimulation or in Ha-ras
transformed cells [48—SQl. Accordingly, lovastatin abolished in-
duction of c-fos mRNA by FCS or growth factors in human
fibroblasts [511. On the other hand, c-jun activity is tightly
regulated by its state of phosphorylation, and transcriptional
regulation may not fully reflect activity of the protein [52].
However, our results demonstrate that, following FCS-stimula-
tion, c-los and c-jun protein expression were both abolished by
p2lras —a-
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lovastatin treatment. Neither c-fos or c-jun proteins are known to
he post-translational ly modified by isoprenylation. Together,
these results and the reversibility of lovastatin-induced inhibition
of c-fos and c-jun protein expression obtained with mevalonate
therefore indicated the implication of an upstream intermediate
in this signaling cascade, which may likely be p21'. Finally,
electrophoretic mobility shift assay clearly established the func-
tional impairment of p21"-activated AP-1 dependent mitogenic
pathway in lovastatin-treated RPT cells. Taking into account the
inhibitory effect of lovastatin on the p21/AP-1 cascade, and the
antiproliferative effect of tyrosinc kinase-receptor/MAP kinase!
AP-1 antagonists, these results indicated that lovastatin-induced
inhibition of the integral p2i'm-AP-i pathway was in all likelihood
Fig. 8. Western blot analysis of tubulin (A),
c-fos (B, C) and c-jun (D, E) protein
expression. Total cell extracts were prepared
from renal proximal tubular epithelial cells
incubated 28 hours in presence or in absence of
5 JLM lovastatin and/or 500 M mevalonate, and
then stimulated with fetal calf serum (FCS).
Nuclear extracts from quiescent and FCS-
stimulated NIH3T3 cells were used as control.
(A) Immunoblot analysis of tubulin expression.
Renal proximal tubular epithelial cells were
incubated 28 hours in absence or in presence of
5 LM lovastatin and/or 500 JLM mevalonate. (B)
Time course of c-fos protein induction in renal
proximal tubular epithelial cells following
stimulation with 5% FCS. (C) Renal proximal
tubular epithelial cells were incubated 28 hours
in absence or in presence of 5 xM lovastatin
and/or 500 ILM mevalonate, and stimulated 90
minutes with 5% FCS. (D) Time course of c-
jun protein expression in untreated or 5 /LM
lovastatin-treated renal proximal tubular
epithelial cells following stimulation with 5%
FCS. (E) Renal proximal tubular epithelial cells
were incubated 28 hours in absence or in
presence of 5 tLM lovastatin and/or 500 .rM
mevalonate, and stimulated 90 minutes with 5%
FCS.
instrumental in the antiproliferative activity of lovastatin in renal
proximal tubular epithelial cells.
The growth inhibitory effect of lovastatin may not be solely
dependent upon inhibition of the p2lm7AP-1-dependcnt mito-
genic pathway. Previous work has indeed demonstrated that
inhibition by lovastatin of p21"-transformed cell growth may be
independent of p2l'' function [53]. Likewise, in a mouse fibro-
blastic cell line, lovastatin arrested cells in GO/Gi although it did
not affect p21'' processing [221. In addition to p21" activation,
several signaling pathways may lead to epithelial cell proliferation
[12]. Finally, the limited inhibition of renal cell proliferation
obtained with the protein farnesyl transferase inhibitor HFPA, or
with c-fos and c-jun antisense oligonucleotides might be one
c-fos
FCS — ÷
Time hours 0
T
C I
c-fos
FCS — +
I I
Lovastatin
Mevalonate
D
c-jun —P
FCS — 30 mm
Lovastatin — —
E
c-jun —.
Lovastatin
Mevalonate
+ + +
— ÷ +
—
— +
90mm 30mm 90mm
+ +
+ +
+
a a a a sap a saps a
AP-1 AP-1 s.
I
Vrtovsnik et at: Lovastatin inhibits renal cell growth 1025
A 12345678 B12345
Fig. 9. Electrophoretic mobility shift assay of AP-! binding activity.
Subconfluent renal proximal tubular epithelial cells were incubated 28
hours with or without 10 .rM lovastatin and/or 500 j.rM mevalonate before
two hours stimulation with fetal calf serum (FCS). Nuclear extracts were
prepared and were analyzed by electrophoretic mobility shift assay for
binding to the consensus sequence of the AP-1 motif. (A) Specificity of
AP-1 shift band formation. Nuclear extracts were prepared from two
hours FCS-stimulated renal proximal tubular epithelial cells, and 10 ig of
proteins were added to each binding reaction. Lane 1, labeled oligonucle-
otide was incubated without protein extract; lane 2, control nuclear
extracts from FCS-treated renal proximal tubular epithelial cells. Binding
of AP-1 was competed with 2.5- to 50-fold molar excess of unlabeled AP-1
consensus oligonucleotide sequence (lanes 3 to 7), or with 50-fold molar
excess of unlabeled unrelated NF-1 oligonucleotide sequence (lane 8). (B)
Renal proximal tubular epithelial cells were incubated without or with
lovastatin (10 M, 28 hr) and/or mevalonate (500 j.rM), and stimulated two
hours with FCS (lanes 3 to 5). Nuclear extracts were prepared, and 16 j.rg
of proteins were added to each binding reaction: lane 1, labeled oligonu-
cleotide was incubated without protein extract; lane 2, unstimulated RPT
cells; lane 3, FCS-stimulated renal proximal tubular epithelial cells; lane 4,
lovastatin-treated renal proximal tubular epithelial cells; lane 5, lovastatin-
and mevalonate-treated renal proximal tubular epithelial cells.
indirect evidence of p21"'/AP-1 independent proliferation in
renal tubule cells; however, in both cases pharmacokinetic restric-
tions to the effects of these antagonists could not be excluded [541.
Conversely, the potent antiproliferative effect of wortmannin, one
inhibitor of the phosphatidyl inositol-3-Ol 1-kinase-activated (P13-
kinase)/MAP kinase signaling cascade, might have indicated the
involvement of an alternate mitogenic pathway. However, the
precise nature and sequence of events which link P13-kinase
activity to p2l" and tubular cell proliferation arc not clearly
defined, and one cannot exclude that wortmannin induced inhi-
bition of P13 kinasc was interrupting p21"5-dependent cascade
Our results indicate that, much like previous studies in mesan-
gial cells, HRI exert a potent antiprolifcrativc effect in cultured
renal epithelial tubule cells [56—58]. HMG CoA reductase activity
is ubiquitously distributed in mammal cells, however, the potency
of HRI effects varies widely among different species and cell types.
Human cultured endothelial cells and fibroblasts appeared more
sensitive to the antiproliferative effect of lovastatin as compared
to rat cells [59, 60]. HRI-concentrations inhibiting RPT cells
proliferation were close to the range of peak plasma concentra-
tions reached in humans on hypocholesterolemic treatment [61].
Moreover, the addition of plasma from fluvastatin-treated pa-
tients to human arterial myocytes in culture was recently reported
to significantly reduce cell growth [62]. Together, these data
suggest that the in vitro reported antiproliferative effect of lova-
statin may be pharmacologically relevant in renal tubule cells in
vivo in humans. The control of tubule cell proliferation would give
the opportunity to address its precise pathophysiological role in
chronic renal diseases, and would potentially delay the progressive
destruction of renal parenchyma in cystic and chronic kidney
diseases. Actually, beneficial effects of lovastatin were demon-
strated in vivo on the glomerulosclerosis of obese Zueker rats and
of Dahl-salt sensitive rats, and in rat 5/6 nephrectomy model
[63—651, as well as decreased cyst formation in male Han:SPRD
polycystic rats [66]. Plasma cholesterol lowering by lovastatin was
a primary goal in these hyperlipidemic diseases. However, in these
studies, the protective effect of lovastatin on glomerulosclerosis
correlated to a decrease in mesangial cell proliferation and
involved inhibition of products of the mevalonate pathway [56,
57]. Accordingly, the antiproliferative effect of lovastatin on
mesangial cells in guinea pigs, in rabbit vascular intimal myocytes,
and in melanoma cells transplanted into mice was observed
independently from any change in plasma cholesterol concentra-
tion [67, 681.
In conclusion, these results demonstrate that renal epithelial
tubule cell growth is highly dependent on mevalonate derived
products, and on p21-activated, c-fos, c-jun dependent mito-
genie pathway. This work provides the rationale for investigation
of the potential effects of lovastatin in vivo, in the regenerating
kidney and p21'-dependent proliferative disorders.
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APPENDIX
IIRI, HMG CoA reductasc inhibitors; FCS, fetal calf serum; BrdUrd,
5-hromo-2'-deoxyuridine-5'-monophosphate; FPP, farriesyl-pyrophos-
phate; GGPP, geranylgeranyl-pyrophosphatc; EGF, epidermal growth
factor; LDL, low density lipoprotein; MTF, 3-[4,5-dimethylthiazol-2-yIJ-
2,5 diphenyl-tetrazolium bromide; PBS, phosphate buffered saline; PBST,
PBS-Tween; PMSF, phenyl methyl sulfonide fluoride; HFPA, a-hydroxy-
farnesyl-phosphonic acid.
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